PubMed Health⌕ Search

PubMed · 11073252

Polyphospha

Abstract

The Eglinton reaction of diethynyl(2,4,6-tri-tert-butylphenyl)phosphane (7a), that is, the oxidative coupling of 3, 4, 5, or 6 of these phosphane units, affords a mixture of the 15-, 20-, 25-, and 30-membered macrocycles 8, 9, 10, and 11. Pure triphosphacyclopentadecahexayne 8 and pentaphosphacyclopentacosadecayne 10 were isolated by HPLC, while the mixture of 9 and 11 could not be separated. Multistep syntheses of open-chain polyphosphapolyynes are described, whose intra- or intermolecular coupling yields the phosphamacrocycles 8, 9, and 11. Eglinton coupling of bis(ethynylphosphanyl)butadiyne (17) gave a mixture of the 20-membered tetraphosphacycloicosaoctayne 9, the 30-membered hexaphosphacyclotriacontadodecayne 11, and the 40-membered octaphosphacyclotetracontahexadecayne 23 as result of a di-, tri-, and tetramerization, respectively. Intramolecular coupling of bis[(ethynylphosphanyl)butadiynyl]phosphane 25a gave 8, while intermolecular coupling gave 11; these two compounds were isolated by chromatography to give yields of 70 and 5%, respectively. The open-chain tetraphosphaeikosaoctayne 28 couples intramolecularly to give 9 and intermolecularly to give the 40-membered octaphosphacyclotetracontahexadecayne 23, which was isolated in the pure form. Octaphosphatetracontahexadecayne 32 cyclized to give 23, exclusively. The temperature-dependent 1H and 31P NMR spectra of the open-chain and cyclic ethynylphosphanes indicated a lowering of the inversion barrier of the tertiary phosphanes from the usual 130-140 kJ mol(-1) to 65-75 kJ mol(-1). Ab initio calculations proved that the dramatic reduction of the inversion barriers results from the interaction of the lone pair on phosphorus with the pi orbitals of the triple bonds in the planar transition state during inversion. The situation is comparable with the dramatic reduction of the P inversion barrier in phospholes, because of the planar, aromatic transition state. The polyphospha[m]cyclo[n]carbons may be considered as precursors to cyclic PmCn systems.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Markl, T Zollitsch, P Kreitmeier, M Prinzhorn, S Reithinger, E Eibler. 2000-10-16. Polyphospha. https://doi.org/10.1002/1521-3765(20001016)6%3A20%3C3806%3A%3Aaid-chem3806%3E3.0.co%3B2-j

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗